Revvity, INC

Revvity, Inc. announced its second quarter 2026 financial results, reporting revenue of $730 million and adjusted EPS of $1.41, while also entering an agreement to divest its China Immunodiagnostics business for up to $200 million.

Revvity, Inc. reported Q1 2026 financial results, including revenue growth and adjusted EPS, while announcing its strategic intent to divest its China Immunodiagnostics business.

Revvity, Inc. shareholders approved an amendment to the company's by-laws allowing holders of 25% of common stock to call special meetings.

Revvity, Inc. reported strong fourth-quarter and full-year 2025 financial results, surpassing expectations and initiating optimistic 2026 guidance.

Revvity, Inc. announced preliminary Q4 and full-year 2025 financial results, expecting to exceed adjusted EPS guidance and reporting solid revenue growth.

Revvity announced third quarter 2025 financial results with $699 million revenue, 1% organic growth, mixed EPS, and raised its full-year adjusted EPS guidance.

Revvity, Inc. announced its first-quarter fiscal year 2026 financial results, showing a 7% increase in total revenue to $711.1 million, while net income saw a slight decrease compared to the prior year.

Revvity, Inc. reported a 2% increase in Q3 2025 revenue to $698.9 million, though gross and operating margins decreased due to tariffs and unfavorable foreign exchange rates.

Revvity, Inc. reported a 4% increase in Q2 2025 revenue, reaching $720.3 million, driven by growth in both Life Sciences and Diagnostics segments, despite a decline in gross margins.

Revvity, Inc. announces a 2% increase in revenue for Q1 2025, driven by growth in its Diagnostics segment and Software revenue within Life Sciences.

Revvity Inc. saw a modest revenue increase and improved operating margins in the third quarter of 2024, driven by growth in its Diagnostics segment.

Revvity, Inc. experienced a slight revenue decrease in Q2 2024, with a 2% drop compared to the same period last year, alongside a decrease in gross margin, but an increase in operating margin.

Revvity, Inc. reported a 4% revenue increase in fiscal year 2025, driven by Diagnostics and Software, but faced declines in net income and gross margins due to tariffs and restructuring costs.

Revvity's fiscal year 2024 saw a slight revenue increase despite challenging market conditions, driven by growth in Diagnostics offsetting a decline in Life Sciences.

Revvity Inc.'s 2023 10-K filing reveals a year of strategic portfolio transformation, including the divestiture of the Applied, Food and Enterprise Services businesses, and a focus on core Life Sciences and Diagnostics segments.

Anita Gonzales, Vice President and CAO of Revvity, Inc., sold 85 shares of common stock on July 20, 2026 for $109.48 per share.

Anita Gonzales, Vice President and CAO of Revvity, Inc., reported a transaction involving the surrender of 33 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Revvity, Inc. Director Alexis P. Michas reported transactions involving restricted stock units and common stock, including grants and holdings in a charitable foundation.

Revvity, Inc. Director Sophie V. Vandebroek acquired restricted stock units, with vesting contingent on continued service and subject to specific change-in-control provisions.

Michael A. Klobuchar, a Director at Revvity, Inc., acquired restricted stock units representing 1,015 shares of common stock on May 7, 2026.

Director Frank Witney acquired 1,015 shares of Revvity Inc. common stock on May 7, 2026, as part of a restricted stock unit grant.

Revvity, Inc. announces its 2026 annual meeting of shareholders, detailing 2025 financial performance, executive compensation, and corporate governance proposals including a reduced shareholder special meeting threshold.

Revvity, Inc. announces its 2025 Annual Meeting and details proposals for shareholder consideration, including director elections, auditor ratification, executive compensation approval, and amendments to corporate governance documents.

Revvity, Inc. has released its proxy statement for the 2025 annual shareholder meeting, detailing proposals for director elections, auditor ratification, executive compensation, and governance amendments.

Revvity, Inc. announces its 2024 Annual Meeting and provides details on voting matters for shareholders.

Revvity, Inc. has released its proxy statement detailing proposals for the upcoming 2024 annual meeting of shareholders, including the election of directors, ratification of the company's accounting firm, and an advisory vote on executive compensation.

Vanguard Capital Management disclosed a beneficial ownership of 8,326,862 shares, representing 7.44% of Revvity Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Revvity Inc. following an internal realignment.

Janus Henderson Group plc has reported a 6.6% beneficial ownership stake in Revvity, Inc. through a Schedule 13G filing.

EdgePoint Investment Group Inc. has reported a 7.39% beneficial ownership stake in Revvity, Inc., holding 8,574,280 common shares.

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 6.8% of Revvity Inc.'s common stock as an investment adviser.

EdgePoint Investment Group Inc. has reported a 5.76% beneficial ownership stake in Revvity, Inc., totaling 6,789,660 common shares.